Navigation Links
ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress
Date:6/4/2009

m. CEST in the Bella Center.

About ACTEMRA(R) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody being studied for the treatment of RA. Studies demonstrate that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five Phase III clinical studies and has enrolled more than 4,000 patients in 41 countries, including the United States. The five Phase III studies are completed and have reported meeting their primary endpoints. ACTEMRA is currently under review by the FDA in the United States.

ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan. ACTEMRA (known as RoACTEMRA in Europe), was also recently approved in the European Union, Switzerland and India.

The serious adverse events reported in ACTEMRA clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension and increased ALT. Increases in liver enzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical out
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis
2. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
5. Studies Reveal Exposure to Pesticides During Pregnancy Increases Risk of Premature Birth, Low-Birth Weight, Neurological Problems and Diabetes
6. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
7. 2 studies examine medical consequences of police use of force during restraint
8. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
9. Studies show LAM patients participate in clinical trials to help others, not themselves
10. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
11. Review finds conflicts of interest in many cancer studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... strengthen brand recognition, national ... BUFFALO, N.Y., Sept. 17 Meritain Health, ... today announced,the name change of recently acquired benefits ... of Meritain Health. Meritain Health acquired Weyco ...
... Va., Sept. 17 LifeNet Health, a leading,biomedical ... "The,Skin & Wound Allograft Institute" in affiliation with ... nation,s largest and most progressive,organ and tissue recovery ... & Wound Institute" will directly serve the needs ...
... affect asthma type, study concludes, , , MONDAY, Sept. ... affect the type of asthma you develop, new ... youngsters in affluent, developed countries had more allergy-triggered ... developed countries. , "The link between atopic ...
... 17, 2007 - In October the American College of ... Health." Edited by Dr. Harvey Makadon, Dr. Ken Mayer, ... Community Health, and Dr. Jennifer Potter of Beth Israel ... current and future medical providers about the unique health ...
... 17 Governor Edward G.,Rendell has appointed 37 individuals ... with chronic disease receive health care in the,future. The ... care reform plan. "About 78 percent of all ... of all patients -- those with chronic diseases,",Governor Rendell ...
... Michael E. Phillips MBA Offers Extensive Hospital, Financial and Capital ... ... Sheets: GSIEF) is pleased to announce that Michael E. Phillips,has been elected ... brings an important dimension to,GSI because of his crossover experience in both ...
Cached Medicine News:Health News:Meritain Health Announces Name Change for Acquired Companies 2Health News:LifeNet Health Establishes 'The Skin & Wound Allograft Institute' 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:American College of Physicians publishes 'The Fenway Guide to LGBT Health' 2Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 2Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 3Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 4Health News:Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA 5Health News:Fund Manager Joins Board of GSI Securitization Inc. 2
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, ... Global Biotechnology, Inc. for the compounding, packaging and distributing of ... in the United States . ... capable of compounding naltrexone tablets in various strengths for individual ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... China, April 19, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese medicines ("TCM") in China, today announced that ... owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd ("Renhuang"), ...
... April 19, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... acquire the rights to ifetroban, a new Phase II ... the brand name Hepatoren™ (ifetroban) Injection and is evaluating ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
The Elecsys 2010 Rack System streamlines processes and allows for smooth implementation of laboratory automation....
Medicine Products: